2006, Drugs and Pharmaceuticals - Drug Discovery Digest

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

SEPTEMBER 20, 2022

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

Drug Channels

OCTOBER 9, 2024

As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. drug wholesaling industry. All rights reserved.

Pharmacy

Pharmacy Drugs Pharmaceuticals Hospitals

Available for Preorder: The 2021-22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

SEPTEMBER 14, 2021

On October 5, 2021, Drug Channels Institute will release The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmaceuticals

Pharmaceuticals Drugs Marketing

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

Drug Channels

DECEMBER 5, 2023

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Tomorrow on Drug Channels , I’ll delve into the pros and cons of this new approach. to 1:30 p.m.

Pharmacy

Pharmacy Drugs Hospitals Pharmaceuticals

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. As we explain below, this accelerating adoption also boosts profits for pharmaceutical wholesalers and specialty distributors—particularly when these channel participants can influence which biosimilar version a provider utilizes. drug distribution.

What Pharmaceutical Manufacturers Value Most from a Hub

Drug Channels

SEPTEMBER 8, 2023

Nasir discusses how hubs help patients initiate and adhere to drug therapies. Based on CareMetx research, he outlines the key factors that drug manufacturers value in their hub partners. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Therapies Production Drugs

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Drug Channels

FEBRUARY 7, 2024

As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. Tomorrow, we’ll be treated to a Senate show trial featuring pharmaceutical company executives.

Pharmaceutical Companies

Pharmaceutical Companies Drugs Pharmaceuticals Trials

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs

Drug Channels

OCTOBER 25, 2021

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar.

Pharmacy

Pharmacy Drugs Pharmaceuticals Hospitals

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Drug Channels

JULY 29, 2022

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. d/b/a Drug Channels Institute.

Pharmacy

Pharmacy Drugs Government Pharmaceuticals

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

Drug Channels

MAY 18, 2023

To learn more about Phil’s access and commercialization solutions, download their free whitepaper, Modernize the Patient Access Experience: Transform Your Pharmaceutical Brand. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. You can also visit [link]. Read on for Patrick’s insights.

Drugs

Drugs Pharmaceuticals

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs (rerun)

Drug Channels

APRIL 21, 2022

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. The video is excerpted from my recent Drug Channels Update: Buy-and-Bill Trends video webinar.

Pharmacy

Pharmacy Drugs Pharmaceuticals Hospitals

NOW AVAILABLE: 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 8, 2024

I am pleased to announce Drug Channels Institute's new 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. pharmaceutical distribution industry. Please contact us if you did not receive your email.

Pharmaceuticals

Pharmaceuticals Licensing Licensing Drugs

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

Drug Channels

JUNE 14, 2022

Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Drugs

Drugs Disease Pharmaceuticals Treatment

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Drug Channels

APRIL 12, 2022

As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. One bright spot: consumers will account for an ever-smaller share of drug spending. Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S.

Pharmacy

Pharmacy Drugs Government Pharmaceuticals

Still Not Skyrocketing: New CMS Data Reinforce the Truth About U.S. Drug Spending

Drug Channels

FEBRUARY 1, 2022

As you will see, outpatient drug spending remains a small—and shrinking—share of the $4.1 What's more, drug spending again grew more slowly than overall healthcare spending. Demonizing pharmaceuticals as a driver of U.S. Demonizing pharmaceuticals as a driver of U.S. d/b/a Drug Channels Institute. healthcare.

Hospitals

Hospitals Drugs Pharmaceuticals

What I (and Others) Told the Senate about the 340B Drug Pricing Program

Drug Channels

AUGUST 8, 2023

Click here to read the Drug Channels Institute letter to Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. I shared my $0.02 How could I not?

Pharmacy

Pharmacy Hospitals Drugs Pharmaceuticals

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

Drug Channels

APRIL 8, 2024

I am pleased to announce the inaugural Drug Channels Leadership Forum ! The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial healthcare system. And of course, I'll be there to moderate the entire event and lead the fireside chats.

Pharmacy

Pharmacy Drugs Government Pharmaceuticals

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

Drug Channels

OCTOBER 17, 2023

These financial firms have assembled significant oncology practice management companies that are primed for purchase by drug channel participants. Nonetheless, I expect this consolidation activity to continue—enabling a new round of vertical integration in the drug channel. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Hospitals Drugs

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

Drug Channels

FEBRUARY 24, 2023

Matt shares three key findings from CareMetx’s exclusive new survey on patient support services for specialty pharmaceuticals. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Matt’s insights.

Pharmaceuticals

Pharmaceuticals Drugs

The Case for Data Unity, Sharing, and Usability

Drug Channels

JUNE 2, 2022

Bonnie describes how pharmaceutical care would benefit from standard medical record identification. To learn more, download the Wolters Kluwer free ebook: Drug Data Unity: Realistic and Idealistic Futures for Information Exchange. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

Building New Data Connections Helps Brands Lower Adherence

Drug Channels

OCTOBER 1, 2022

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Kylie’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Production Drugs

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Drug Channels

MARCH 22, 2024

He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report. Read on for Adam’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Therapies Pharmaceuticals Drugs

Building New Data Connections Helps Brands Lower Adherence Barriers

Drug Channels

OCTOBER 1, 2022

Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read on for Kylie’s insights.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Production Drugs

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Drug Channels

APRIL 1, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription. Click here to see the original post from December 2023.

Pharmacy

Pharmacy Hospitals Pharmaceuticals Drugs

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A 2022 Update

Drug Channels

OCTOBER 13, 2022

pharmaceutical distribution, payment, and reimbursement system. drug channels. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. But there are two slides that people seem to appreciate the most.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

Drug Channels

SEPTEMBER 21, 2022

In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. The battle for control of the specialty patient continues.

Specialty Pharmacies

Specialty Pharmacies Hospitals Pharmacy Pharmaceuticals

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals

Pharmaceuticals Biosimilars Licensing Licensing

NEW: The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. Twice a year, I spend my evenings and weekends writing two comprehensive, fact-based, and nonpartisan reports on drug channel economics.

Pharmaceuticals

Pharmaceuticals Biosimilars Licensing Licensing

How CVS Health Drives Cardinal Health’s Distribution Financials

Drug Channels

SEPTEMBER 9, 2021

In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago. The two wholesalers sell more than $90 billion in pharmaceuticals to CVS Health—making it the largest U.S. drug purchaser. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmaceuticals

Pharmaceuticals Marketing Drugs Pharmacy

Informa Connect's Life Sciences Commercial Contracts & Chargebacks 2022 Hybrid

Drug Channels

APRIL 11, 2022

Visit informaconnect.com/contracts-chargebacks to view the complete agenda, then register using the exclusive Drug Channels discount code 22DC10 to receive 10% off ! Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net).

Science

Science Pharmaceuticals Drugs

New SingleCare Pharma Solutions Help Drugmakers Reach Cash-Paying Patients

Drug Channels

JULY 13, 2023

Today’s guest post comes from Josh Bliss, SVP of Customer Acquisition and Head of Pharma Solutions at SingleCare Josh discusses the challenges that pharmaceutical manufacturers face connecting with consumers who could benefit from patient financial support programs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals

Pharmaceuticals Marketing Drugs

White Bagging Update: PBMs’ Specialty Pharmacies Keep Gaining on Buy-and-Bill Oncology Channels

Drug Channels

OCTOBER 12, 2021

specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. White bagging can boost profits and revenues for PBM-owned specialty pharmacies while increasing payers’ control over hard-to-manage medical benefit drugs.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Hospitals Pharmaceuticals

How CVS Health Drives Cardinal Health’s Distribution Financials (rerun)

Drug Channels

DECEMBER 16, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Outlook 2022. In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago. drug purchaser. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs Pharmacy

Four Solutions Manufacturers Should Consider For Retail and Specialty-lite Products

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Michael’s insights.

Specialty Pharmacies

Specialty Pharmacies Production Pharmacy Therapies

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

OCTOBER 4, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. d/b/a Drug Channels Institute.

Pharmaceuticals

Pharmaceuticals Drugs

Improving Out-of-Pocket Cost Transparency For Physicians

Drug Channels

AUGUST 12, 2022

Divya then explains how GoodRx partners with pharmaceutical companies to improve cost transparency and communication between patients and providers. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceuticals Drugs Research

White Bagging Update 2023: Saving Money or Shifting Costs?

Drug Channels

SEPTEMBER 13, 2023

Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations (rerun)

Drug Channels

OCTOBER 2, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Click here to see the original post from May 2023.

Pharmacy

Pharmacy Pharmaceuticals Marketing Drugs

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

Drug Channels

MAY 10, 2022

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. healthcare expenditures.

Pharmaceuticals

Pharmaceuticals Drugs

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

Drug Channels

DECEMBER 13, 2023

This week, I’m rerunning some popular posts while I prepare for Fiday's Drug Channels Outlook 2024 live video webinar. Time for our annual update on the channels for provider-administered drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Specialty Pharmacies

Specialty Pharmacies Pharmacy Pharmaceuticals Drugs

Drug Channels News Roundup, October 2021: PBMs’ Oncology Exclusions, Biosimilar Boom, BCBS vs. Hospitals, U.S. vs. the World, and CRISPR Comedy

Drug Channels

OCTOBER 27, 2021

So grab your pillow case and stuff it with treats from the great Drug Channels pumpkin patch: Spooky! PBMs are conjuring a terrifying number of formulary exclusions for oncology drugs Eerie! drug spending shambles into the middle of the herd Plus, The Onion summons the only humorous article about CRISPR. Brrr.did you hear that?

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

JULY 28, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. That’s why I refer to them as drug pricing flat earthers (#DPFE).

Pharmaceuticals

Pharmaceuticals Drugs

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Drug Channels

MAY 24, 2023

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. to 1:30 p.m.

Pharmacy

Pharmacy Pharmaceuticals Marketing Drugs

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Drug Channels

JUNE 13, 2023

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. to 1:30 p.m.

Pharmaceuticals

Pharmaceuticals Drugs

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

Webinars

Trending Sources

Available for Preorder: The 2021-22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

Webinars

Drug Wholesalers and Brand-Name Drug Prices: Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s

How the Biosimilar Boom Boosts Drug Wholesalers’ Profits

What Pharmaceutical Manufacturers Value Most from a Hub

Latest CMS Data Reveal the Truth About U.S. Drug Spending

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Four Ways for Field Teams to Tackle Drug Utilization Management and Optimize Patient Access

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs (rerun)

NOW AVAILABLE: 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Still Not Skyrocketing: New CMS Data Reinforce the Truth About U.S. Drug Spending

What I (and Others) Told the Senate about the 340B Drug Pricing Program

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

The Case for Data Unity, Sharing, and Usability

Building New Data Connections Helps Brands Lower Adherence

Three Digital Intake Strategies For Eliminating Patient Enrollment Forms

Building New Data Connections Helps Brands Lower Adherence Barriers

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A 2022 Update

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

NEW: The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

NEW: The 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

How CVS Health Drives Cardinal Health’s Distribution Financials

Informa Connect's Life Sciences Commercial Contracts & Chargebacks 2022 Hybrid

New SingleCare Pharma Solutions Help Drugmakers Reach Cash-Paying Patients

White Bagging Update: PBMs’ Specialty Pharmacies Keep Gaining on Buy-and-Bill Oncology Channels

How CVS Health Drives Cardinal Health’s Distribution Financials (rerun)

Four Solutions Manufacturers Should Consider For Retail and Specialty-lite Products

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers (rerun)

Improving Out-of-Pocket Cost Transparency For Physicians

White Bagging Update 2023: Saving Money or Shifting Costs?

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations (rerun)

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

Drug Channels News Roundup, October 2021: PBMs’ Oncology Exclusions, Biosimilar Boom, BCBS vs. Hospitals, U.S. vs. the World, and CRISPR Comedy

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers

Stay Connected